Teva Pharmaceuticals has agreed to a $450 million settlement with the U.S. government to resolve allegations of violating the Anti-Kickback Statute and False Claims Act. The settlement stems from accusations that Teva engaged in two unlawful kickback schemes involving the multiple sclerosis drug Copaxone and price-fixing of generic drugs. This settlement is the largest among a series of cases targeting pharmaceutical companies for unlawfully paying patient copays through third-party foundations.
Results for: Teva Pharmaceuticals
JP Morgan assesses the Specialty Pharmaceuticals sector, highlighting the resurgence of interest in new product launches. While the core fundamentals have strengthened, overall growth remains modest. The analyst offers insights into specific companies, providing ratings and outlining potential opportunities and concerns.